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 CURRENTOPINION Myositis autoantibodies: recent perspectives
Victoria RiddellAQ2
a, Stefan Bagbya, and Neil McHughb
Purpose of review
To provide an overview of recent discoveries related to myositis-specific autoantibodies (MSAs) and assays
used for their measurement.
Recent findings
New autoantibody specificities have been reported including a MSA directed against eukaryotic initiation
factor 3 and a myositis-associated autoantibody directed against heat shock factor 1. The association of
anti-TIF1g with cancer-associated dermatomyositis dependent on age has been confirmed in several large
cohorts. Despite MSAs being almost entirely mutually exclusive, several myositis autoantigens are
overexpressed in regenerating muscle and do not correlate with the corresponding MSA in any one
patient. Further mechanisms may determine the final MSA specificity and are likely to include the need for
autoantigen processing and presentation with adaptive T-cell help. The presence of CD4-positive T cells
specific for histidyl tRNA synthetase protein in bronchial lavage fluid from antisynthetase patients lends
support to this view. Finally, it is widely held that MSA do play an important role in clinical practice among
some evidence and concern about commercial assay reliability.
Summary
MSAs continue to provide important tools for clinical diagnosis and management as well as insights into
disease mechanisms. Further improvement in the standardization and reliability of routine detection of
MSAs is a high priority.
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INTRODUCTION
Idiopathic inflammatory myopathies (IIMs)
describe a group of disorders characterized by mus-
cle inflammation. IIMs are traditionally described
within subcategories: polymyositis, dermatomyo-
sitis, and inclusion body myositis. These subtypes
categorize IIMs primarily according to the extent
of muscle and skin involvement in the disease, but
they fail to capture accurately the diversity of
clinical symptoms [1]. Autoantibodies are hall-
marks of IIMs and are described as either myosi-
tis-specific autoantibodies (MSAs) or myositis-
associated autoantibodies (MAAs). MAAs can occur
in conjunction with another autoantibody and are
found in other connective tissue diseases, whereas
MSAs are exclusively found in myositis patients
and only rarely occur together [2&]. MSAs are
strongly associated with clinical features and can
be used to define phenotypic subtypes. The pres-
ence of a particular MSA provides important prog-
nostic information with regard to disease
development and treatment response. The purpose
of this review is to consider recent developments
involving MSAs, focusing on the discovery of novel
autoantibodies and the development of MSA assays
for patient testing.
SUMMARY OF KNOWN MYOSITIS-
SPECIFIC AUTOANTIBODIES
Autoantibodies are detected in up to 60% of myosi-
tis patients, providing key information relating to
associated clinical features and prognosis. MSAs
identified to date, and their clinical associations,
are summarized in Table 1. Identification of an
MSA can increase diagnostic confidence, direct dis-
ease management and help avoid unnecessary treat-
ment [2&,3].
Currently, around 40% of IIM patients will
exhibit no detectable autoantibody, providing a
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diagnostic challenge that requires alternative tools
[2&]. There is, moreover, limited prognostic informa-
tion available for this group, potentially complicat-
ing disease management and affecting treatment
plans. Discovery of novel autoantibodies is therefore
crucial to advancing current diagnostic practices
and defining new clinical subgroups.
NOVEL AUTOANTIGENS
A novel autoantibody directed against a small pro-
tein, eukaryotic initiation factor 3 (eIF3), has been
identified in a small number of myositis patients,
with no other MSAs present [4&]. While occurring
in only 0.44% of patients, anti-eIF3 appears associ-
ated with mild myopathy, absence of cancer or inter-
stitial lung disease and a favourable response to
treatment. Notably, anti-eIF3 yields weak or absence
of nuclear staining and fine cytoplasmic speckling on
indirect immunofluorescence so may be overlooked
on routine screening. Therefore, the anti-eIF3-posi-
tive patient group may be at high risk of misdiagnosis
which would result in under-representation in obser-
vational cohorts of myositis patients. Of interest eIF3
plays a key role in skeletal muscle regulation.
Another recent finding has been the finding of
autoantibodies directed against heat shock factor 1
(HSF1) by screening a human protein microarray
and confirmation using a combination of other
assays [5&]. Anti-HSF1 was present in 11% of IIM
patients from a large Chinese cohort and more
prevalent in cancer-associated myositis (CAM)
(17.2%) compared with non-CAM patients (7.5%).
Levels of anti-HSF1 also seemed to mirror disease
activity in noncancer patients. Consistent with
what has been found with some other myositis
autoantigens, expression of HSF1 was increased in
regenerating muscle cells of myositis muscle tissue.
KEY POINTS
! Antieukaryotic initiation factor 3 is a novel MSA found
in a small number of myositis patients but may be
under-recognized in routine screening.
! Although MSA very infrequently coexist in the same
patient RNA of several myositis autoantigens are highly
expressed in muscle biopsy samples from
myositis patients.
! MSA testing is widely used to inform clinical practice
despite some concerns about assay performance.
Table 1. Currently identified myositis-specific autoantibodies and their clinical associations
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Anti-TIF1g Transcription intermediary factor 1g Adult 7%
Juvenile 18–30%
Malignancy in adults
DM typical skin rashes
Cutaneous photosensitivity
‘Red-on-white’ lesions




‘Classic’ DM with typical skin
rashes




DM typical skin rashes
Later muscle involvement
Anti-NXP2 Nuclear matrix protein 2 Adult 2–17%
Juvenile 15–20% AQ7
Severe onset muscle disease
DM typical skin rashes
Malignancy






ARS, aminoacyl-tRNA synthetase; DM, dermatomyositis; EJ, glycyl-tRNA synthetase; HA, tyrosyl-tRNA synthetase; HMGCR, 3-hydroxy-3-methylglutaryl CoA reductase;
IIM, idiopathic inflammatory myopathy; ILD, interstitial lung disease; Jo1, histidyl-tRNA synthetase; KS, asparagyl-tRNA synthetase; MDA5, melanoma differentiation
associated protein 5; NXP2, nuclear matrix protein 2; OJ, isoleucyl-tRNA synthetase; PL12, alanyl-tRNA synthetase; PL7, threonyl-tRNA synthetase; SAE, small
ubiquitin-like modifier activating enzyme; SRP, signal recognition particle; TIF1g, transcription intermediary factor 1g; Zo, phenylalanyl-tRNA synthetase.
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However, anti-HSF1 was also found in similar fre-
quency in other autoimmune rheumatic disease
controls so does not appear to an MSA.
The same group have reported autoantibodies to
poly-U-binding factor 60-kDa protein (PUF60) mea-
sured by ELISA in 10.6% (41/388) of Chinese
patients with IIM [6], but again not myositis specific
as anti-PUF60 was present in a similar frequency in
disease controls. PUF60 was initially reported as a
novel autoantigen by Fiorentino et al. in 2015 [7]
with anti-PUF60 present in a range of rheumatic
diseases and most commonly found in systemic
sclerosis (30%) and dermatomyositis (18%). In the
latter study in dermatomyositis anti-PUF60 was
associated with the presence of anti-TIF1g, whereas
in the Chinese population anti-PUF60 was detected
in clinically amyopathic dermatomyositis (CADM)
patients and dermatomyositis patients without cur-
rently known myositis autoantibodies. Anti-PUF60
was associated with skin ulcerations and in eight
patients followed longitudinally antibody levels
declined with disease remission. Several previous
studies have suggested a correlation between MSA
titre and disease activity especially in relation to
anti-MDA5 [8–10] although it is still unclear if
antibody titres can provide reliable measurements
to assess treatment response.
ANTI-TIF1 SPECIFICITY AND CANCER
The association of anti-TIF1g and cancer in patients
with dermatomyositis is now well established with
up to 50% of anti-TIF1g-positive patients develop-
ing an associated cancer within 3 years of myositis
onset [11,12]. In a cohort of 263 dermatomyositis
cases from the United Kingdom all detected anti-
TIF1g malignancy cases occurred between 3 years
prior to and 2.5 years after dermatomyositis onset
[13]. Ovarian cancer was particularly common sug-
gesting the need for specific screening strategies. Of
interest no anti-TIF1g-positive case less than 39 years
of age developed cancer. The association of anti-
TIF1g and cancer dependent on age was further
shown in a large EuroMyositis registry of 1637
patients where the significant association between
anti-TIF1g and CAM only existed for patients more
than 58 years of age [2&]. The lack of an association
between anti-TIF1g and cancer in younger patients
with dermatomyositis and indeed in juvenile
dermatomyositis suggests that the generation of
autoantibodies in this context is not tumour driven
and reflects an intrinsically different molecular
mechanism, or else that younger patients are unwit-
ting survivors of a tumorigenic event. In a combined
Swedish and Spanish cohort levels of anti-TIF1g
declined with successful treatment of cancer [14],
indeed suggesting here the cancer itself is driving
the autoimmune response.
The IgG subclass of anti-TIF1g may provide
additional prognostic information. In a European
cohort, 90% of dermatomyositis patients positive
for anti-TIF1g IgG2 subclass had a positive cancer
diagnosis, rising to a 100% predictive value for
cancer using a higher cut-off level [15&]. All cases
occurred within 2 years of follow-up.
Antibodies to TIF1g may also target other mem-
bers of the TIF1 family of proteins [16]. A small
number of patients may target TIF1b alone. Seven
such patients (2.4%) were identified from 292
patients positive for at least one anti-TIF1 antibody
[17]. Six of the seven had dermatomyositis, two of
whom had CADM, one had cancer and none of
seven had interstitial lung disease. Although the
numbers were small the authors suggested anti-
TIF1b may be associated with a milder form of
dermatomyositis. Given that all the TIF1 family of
proteins have roles in tumorigenesis, future investi-
gation of the expression of TIF proteins in various
tissues and environments, and the effects of post-
translational modification of TIF1 proteins, could
provide key insights [18].
MYOSITIS-SPECIFIC AUTOANTIBODY
GENERATION
Recent studies are of interest in providing possible
insights into how MSAs are generated. First, MSAs
are almost always mutually exclusive. In the large
EuroMyositis registryonlythreecases (0.2%)hadmore
than one MSA [2&]. Therefore, one may expect that the
presence of a MSA in any individual patient may
correspond to the corresponding autoantigen being
overexpressedinthediseasedtissue.However,inaRNA
sequencingstudyof106musclebiopsiesofIIMpatients
the increased expression of a given autoantigen in
myositis muscle was not associated with autoantibod-
ies recognizing that autoantigen [19&&]. Instead most
myositis autoantigens were highly expressed and cor-
related with marker of muscle regeneration. Conse-
quently, there is likely to be other prerequisites in
additionto theactualmyositis autoantigenexpression
that determines the MSA specificity.
One important mechanism that may influence
the generation of a MSA response and overcome self-
tolerance is the presence of T-cell help. In this regard
the finding of CD4" cells in bronchial lavage fluid
from three of four antisynthetase patients fluid
responsive to histidyl-tRNA synthetase (HisRS) pro-
tein (HisRS) is notable [20&]. Peripheral blood mono-
cytes also responded to HisRS protein in the majority
(10/14) of antisynthetase patients, although such a
response was also seen in a number of controls.
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Together with identifying the presence of anti-Jo-1
antibodies in bronchial lavage fluid, the authors
surmised that immune reaction to HisRS protein
may occur in the lungs of patients with antisynthe-
tase syndrome.
Finally, in an epitope mapping study utilizing
the microbial and autoantigen repertoire of 20
dermatomyositis patients positive for anti-TIF1g
versus 20 controls [21]. Three linear epitopes of
six amino acid length were highly specific for
SARS-CoV-2. One of the epitopes ‘DDAVVC’ in
the RNA-dependent RNA polymerase protein is a
highly ranked CD8 T-cell predicted epitope. The
authors speculate that latent exposure to the Coro-
naviridae family may possibly be an important trig-
ger for the development of myositis.
RECENT ADVANCES IN MYOSITIS-
SPECIFIC AUTOANTIBODY ASSAYS
Developing a reliable MSA detection assay is chal-
lenging. Immunoprecipitation is the reference stan-
dard test for detection and is often used in the
discovery of novel autoantibodies, with confirma-
tion through techniques such as immunoblotting
and mass spectrometry. However, immunoprecipi-
tation requires specialist equipment in a profes-
sional laboratory, and results can take weeks to be
obtained. This limits the utility of immunoprecipi-
tation for routine testing of patient samples, so the
development of commercial MSA assays is required.
Currently available MSA assays may provide a quick
and less expensive option for MSA testing, although
the reliability of commercial assays is a concern and
MSA assay validation is difficult. A recent survey of
members of the International Myositis Assessment
and Clinical Studies Group showed that despite the
majority of responders having concerns over assay
reliability, there was widespread use of assay results
informing diagnosis and clinical decision-making
[22]. The standardization and validation of commer-
cial MSA assays is a high priority going forward.
Evaluations and comparisons of currently avail-
able MSA immunoassays report conflicting results
[23&,24–27]. The inability to detect rare MSAs has
raised the issue of whether certain MSAs are under-
reported. For example, eight anti-tRNA synthetase
antibodies (anti-ARSs) have been identified to date
as MSAs. Anti-OJ is an anti-ARS antibody which is
thought to be present in fewer than 1% of myositis
patients [28]. In multiple studies, line and dot blot
immunoassays failed to detect anti-OJ despite posi-
tive confirmation by immunoprecipitation [29,30].
Similarly, an ELISA system designed to detect anti-
ARS antibodies failed to detect anti-OJ [31]. Novel
immunoassays which account for the complexity of
antigen–antibody interactions, for example, con-
formational epitopes, may be required to detect
rarer, probably under-reported antibodies [32].
The rate of false negatives in the detection of anti-
TIF1g hasbeenreportedtobeashigh as76%[23&]. This
is consistent across studies evaluating assay perfor-
mance [24,27]. Anti-TIF1g is highly associated with
malignancy in adult patients, and as such is a key
biomarker for cancer diagnosis [2&,33]. Anti-TIF1g is
reported in 20–30% of juvenile patients, and a false
negative result would result in misdiagnosis [3]. The
low sensitivity of anti-TIF1g detection in commercial
line blot and dot blot immunoassays indicates that
anti-TIF1g is unable to interact with the denatured
antigen, indicating a conformational epitope [23&,33].
Conversely, recent investigations indicate that cross-
reactivity with anti-Mi2 will result in an increased rate
of anti-TIF1g false positive results [34].
A high rate of false positives in MSA testing is a
concern as it could mislead patient diagnosis and
treatment. Commercial immunoassays have been
reported to produce false positive rates as high as
17% [23&,24–27]. Line blot immunoassays allow for
simultaneous testing for multiple MSAs, which
increases the efficiency of testing but additionally
increases the rate of false positives. As MSAs are
mutually exclusive, a positive result for two MSAs
may well indicate a false positive result. It has been
suggested that false positive rates can be decreased
by defining clear, antibody-specific thresholds for a
positive result [26,27]. Using more stringent cut-offs
in one study, the rate of positive results for anti-ARS
antibodies was decreased by almost 30%, with no
patient below the cut-off having antisynthetase syn-
drome at the time of testing [35].
The recent emergence of a novel particle-based
multianalyte assay (PMAT) presents an alternative
to commercial line and dot blot assays. A number of
studies have investigated the reliability of this novel
technology [27,36,37]. Comparison of immune line
blot assays (ILA), immunoprecipitation and PMAT
shows that PMAT results are more closely correlated
to immunoprecipitation results than ILA results
[27], but variable results are reported between spe-
cific antibodies [36]. The use of PMAT as an alterna-
tive MSA assay requires further evaluation larger
cohorts with an increased number of controls.
CONCLUSION
The detection of an MSA can provide a clear diagnosis
and critical prognostic information. Currently, 40%
ofmyositispatientsdo nothaveadetectableMSA; the
discovery of novel autoantibodies may define new
clinical IIM subgroups and allow earlier diagnosis.
Study of novel autoantibodies may also shed light on
Myositis and myopathies
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the pathogenic mechanisms of IIM, facilitating a
broader and deeper understanding of the disease.
Affordable and reliable commercial testing of MSAs
is a high priority; current assays require standardiza-
tion and greater validation in studies with larger
cohorts and more controls. Novel MSA assays to
detect MSAs with more complex antigen interactions
are also worthy of investigation.
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